Importer of Controlled Substances Application: Experic LLC, 53494 [2022-18744]
Download as PDF
<![CDATA[
53494
Federal Register / Vol. 87, No. 168 / Wednesday, August 31, 2022 / Notices
written notifications disclosing all
changes in membership.
On May 28, 2009, Pistoia Alliance,
Inc. filed its original notification
pursuant to section 6(a) of the Act. The
Department of Justice published a notice
in the Federal Register pursuant to
section 6(b) of the Act on July 15, 2009
(74 FR 34364).
The last notification was filed with
the Department on February 28, 2022. A
corrected notice was published in the
Federal Register pursuant to section
6(b) of the Act on July 20, 2022 (87 FR
43298).
Suzanne Morris,
Chief, Premerger and Division Statistics,
Antitrust Division.
[FR Doc. 2022–18817 Filed 8–30–22; 8:45 am]
BILLING CODE 4410–11–P
need to resubmit the same comment. All
requests for a hearing must be sent to:
(1) Drug Enforcement Administration,
Attn: Hearing Clerk/OALJ, 8701
Morrissette Drive, Springfield, Virginia
22152; and (2) Drug Enforcement
Administration, Attn: DEA Federal
Register Representative/DPW, 8701
Morrissette Drive, Springfield, Virginia
22152. All requests for a hearing should
also be sent to: Drug Enforcement
Administration, Attn: Administrator,
8701 Morrissette Drive, Springfield,
Virginia 22152.
SUPPLEMENTARY INFORMATION: In
accordance with 21 CFR 1301.34(a), this
is notice that on July 7, 2022, Experic
LLC, 2 Clarke Drive, Cranbury, New
Jersey 08512–3619, applied to be
registered as an importer of the
following basic class(es) of controlled
substance(s):
DEPARTMENT OF JUSTICE
Controlled substance
Drug Enforcement Administration
Marihuana Extract ....
Marihuana .................
Tetrahydrocannabinols.
Psilocybin .................
5-Methoxy-N–NDimethyltryptamine.
Psilocyn ....................
Nabilone ...................
[Docket No. DEA–1072]
Importer of Controlled Substances
Application: Experic LLC
Drug Enforcement
Administration, Justice.
ACTION: Notice of application.
AGENCY:
Experic LLC has applied to be
registered as an importer of basic
class(es) of controlled substance(s).
Refer to Supplementary Information
listed below for further drug
information.
DATES: Registered bulk manufacturers of
the affected basic class(es), and
applicants therefore, may submit
electronic comments on or objections to
the issuance of the proposed registration
on or before September 30, 2022. Such
persons may also file a written request
for a hearing on the application on or
before September 30, 2022.
ADDRESSES: The Drug Enforcement
Administration requires that all
comments be submitted electronically
through the Federal eRulemaking Portal,
which provides the ability to type short
comments directly into the comment
field on the web page or attach a file for
lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon submission
of your comment, you will receive a
Comment Tracking Number. Please be
aware that submitted comments are not
instantaneously available for public
view on https://www.regulations.gov. If
you have received a Comment Tracking
Number, your comment has been
successfully submitted and there is no
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
16:59 Aug 30, 2022
Jkt 256001
Drug
code
Schedule
7350
7360
7370
I
I
I
7437
7431
I
I
7438
7379
I
II
The company plans to import drug
code 7437 (Psilocybin) and Psilocyn
(7438) as bulk powder and Marihuana
Extract (7350), Marihuana (7360)
Tetrahydrocannabinols (7370) and
Nabilone (7379) as finished dosage units
for research and clinical trial purposes.
No other activity for this drug code is
authorized for this registration.
Approval of permit applications will
occur only when the registrant’s
business activity is consistent with what
is authorized under 21 U.S.C. 952(a)(2).
Authorization will not extend to the
import of Food and Drug
Administration-approved or nonapproved finished dosage forms for
commercial sale.
Kristi O’Malley,
Assistant Administrator.
[FR Doc. 2022–18744 Filed 8–30–22; 8:45 am]
BILLING CODE P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–372]
Exempt Chemical Preparations Under
the Controlled Substances Act
Drug Enforcement
Administration, Department of Justice.
AGENCY:
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
Order with opportunity for
comment.
ACTION:
The applications for exempt
chemical preparations received by the
Drug Enforcement Administration
(DEA) between August 30, 2021, and
March 31, 2022, as listed below, were
accepted for filing and have been
approved or denied as indicated.
DATES: Interested persons may file
written comments on this order in
accordance with 21 CFR 1308.23(e).
Electronic comments must be
submitted, and written comments must
be postmarked, on or before October 31,
2022. Commenters should be aware that
the electronic Federal Docket
Management System will not accept
comments after 11:59 p.m. eastern time
on the last day of the comment period.
ADDRESSES: To ensure proper handling
of comments, please reference ‘‘Docket
No. DEA–372’’ on all correspondence,
including any attachments.
Electronic comments: DEA encourages
that all comments be submitted through
the Federal eRulemaking Portal, which
provides the ability to type short
comments directly into the comment
field on the web page or to attach a file
for lengthier comments. Please go to
https://www.regulations.gov and follow
the online instructions at that site for
submitting comments. Upon completion
of your submission you will receive a
Comment Tracking Number for your
comment. Please be aware that
submitted comments are not
instantaneously available for public
view on Regulations.gov. If you have
received a comment tracking number,
your comment has been successfully
submitted and there is no need to
resubmit the same comment.
Paper comments: Paper comments
that duplicate the electronic submission
are not necessary and are discouraged.
Should you wish to mail a comment in
lieu of an electronic comment, it should
be sent via regular or express mail to:
Drug Enforcement Administration,
Attention: DEA Federal Register
Representative/DRW, 8701 Morrissette
Drive, Springfield, Virginia 22152.
FOR FURTHER INFORMATION CONTACT:
Terrence L. Boos, Ph.D., Diversion
Control Division, Drug Enforcement
Administration; Mailing Address: 8701
Morrissette Drive, Springfield, Virginia
22152; Telephone: (571) 362–8201.
SUPPLEMENTARY INFORMATION:
SUMMARY:
Posting of Public Comments
Please note that all comments
received are considered part of the
public record and made available for
public inspection online at https://
E:\FR\FM\31AUN1.SGM
31AUN1
]]>Agencies
[Federal Register Volume 87, Number 168 (Wednesday, August 31, 2022)]
[Notices]
[Page 53494]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-18744]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA-1072]
Importer of Controlled Substances Application: Experic LLC
AGENCY: Drug Enforcement Administration, Justice.
ACTION: Notice of application.
-----------------------------------------------------------------------
SUMMARY: Experic LLC has applied to be registered as an importer of
basic class(es) of controlled substance(s). Refer to Supplementary
Information listed below for further drug information.
DATES: Registered bulk manufacturers of the affected basic class(es),
and applicants therefore, may submit electronic comments on or
objections to the issuance of the proposed registration on or before
September 30, 2022. Such persons may also file a written request for a
hearing on the application on or before September 30, 2022.
ADDRESSES: The Drug Enforcement Administration requires that all
comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into
the comment field on the web page or attach a file for lengthier
comments. Please go to https://www.regulations.gov and follow the
online instructions at that site for submitting comments. Upon
submission of your comment, you will receive a Comment Tracking Number.
Please be aware that submitted comments are not instantaneously
available for public view on https://www.regulations.gov. If you have
received a Comment Tracking Number, your comment has been successfully
submitted and there is no need to resubmit the same comment. All
requests for a hearing must be sent to: (1) Drug Enforcement
Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive,
Springfield, Virginia 22152; and (2) Drug Enforcement Administration,
Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive,
Springfield, Virginia 22152. All requests for a hearing should also be
sent to: Drug Enforcement Administration, Attn: Administrator, 8701
Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this
is notice that on July 7, 2022, Experic LLC, 2 Clarke Drive, Cranbury,
New Jersey 08512-3619, applied to be registered as an importer of the
following basic class(es) of controlled substance(s):
------------------------------------------------------------------------
Controlled substance Drug code Schedule
------------------------------------------------------------------------
Marihuana Extract..................... 7350 I
Marihuana............................. 7360 I
Tetrahydrocannabinols................. 7370 I
Psilocybin............................ 7437 I
5-Methoxy-N-N-Dimethyltryptamine...... 7431 I
Psilocyn.............................. 7438 I
Nabilone.............................. 7379 II
------------------------------------------------------------------------
The company plans to import drug code 7437 (Psilocybin) and
Psilocyn (7438) as bulk powder and Marihuana Extract (7350), Marihuana
(7360) Tetrahydrocannabinols (7370) and Nabilone (7379) as finished
dosage units for research and clinical trial purposes. No other
activity for this drug code is authorized for this registration.
Approval of permit applications will occur only when the
registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2).
Authorization will not extend to the import of Food and Drug
Administration-approved or non-approved finished dosage forms for
commercial sale.
Kristi O'Malley,
Assistant Administrator.
[FR Doc. 2022-18744 Filed 8-30-22; 8:45 am]
BILLING CODE P
